The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta(2)-microglobulin-deficient BALB/c mice.
Open accessAbstract
Continuous administration of soluble proteins, delivered over a 10-d period by a mini-osmotic pump implanted subcutaneously, induces a long-lasting inhibition of antigen-specific T cell proliferation in lymph node cells from BALB/c mice subsequently primed with antigen in adjuvant. The decreased T cell proliferative response is associated with a down-regulation of the T helper cell (Th)1 cytokines interleukin (IL)-2 and interferon (IFN)-gamma and with a strong increase in the secretion of the Th2 cytokines IL-4 and IL-5 by antigen specific CD4+ T cells. This is accompanied by predominant inhibition of antigen-specific antibody production of IgG2a and IgG2b, rather than IgG1 isotype. Interestingly, inhibition of Th1 and priming of Th2 cells is also induced in beta(2) microglobulin-deficient BALB/c mice, indicating that neither CD8+ nor CD4+ NK1.1+ T cells, respectively, are required. The polarization in Th2 cells is stably maintained by T cell lines, all composed of CD4+/CD8- cells expressing T cell receptor for antigen (TCR) alpha/beta chains, derived from BALB/c mice treated with continuous antigen administration, indicating that they originate from Th2 cells fully differentiated in vivo. This polarization is induced in BALB/c mice by continuous administration of any protein antigen tested, including soluble extracts from pathogenic microorganisms. Priming of Th2 cells is dose dependent and it is optimal for low rather than high doses of protein. Blocking endogenous IL-4 in vivo inhibits expansion of antigen-specific Th2 cells, but does not restore IFN-gamma production by T cells from mice treated with soluble antigen-specific Th2 cells, but does not restore IFN-gamma production by T cells from mice treated with soluble antigen, indicating the involvement of two independent mechanisms. Consistent with this, Th2 cell development, but not inhibition of Th1 cells, depends on non-major histocompatibility complex genetic predisposition, since the Th2 response is amplified in BALB/c as compared to DBA/2, C3H, or C57BL/6 mice whereas tested. These findings support the hypothesis that continuous release of low amounts of protein antigens from pathogenic microorganisms may polarize the immune response toward a Th2 phenotype in susceptible mouse strains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Powrie, F., Correa-Oliveira, R., Mauze, S., & Coffman, R. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.589 · Cited by 613
Cited by
INDUCTION OF TH1 AND TH2 CD4+T CELL RESPONSES:The Alternative Approaches
Constant, S. L., & Bottomly, K. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.297 · Cited by 1,459
MOUSE CD1-SPECIFIC NK1 T CELLS: Development, Specificity, and Function
Bendelac, A., Rivera, M. N., Park, S.-H., & Roark, J. H. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.535 · Cited by 1,326
Noben-Trauth, N., Shultz, L. D., Brombacher, F., Urban, J. F., Gu, H., & Paul, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10838 · Cited by 344
Vaccine adjuvants: Current challenges and future approaches
Wilson-Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J., & Narasimhan, B. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21523 · Cited by 296
Noverr, M. C., Falkowski, N. R., McDonald, R. A., McKenzie, A. N., & Huffnagle, G. B. (2005) · Infection and Immunity · doi:10.1128/iai.73.1.30-38.2005 · Cited by 281
Metadata
- Authors
- Guery, J. C., Galbiati, F., Smiroldo, S., & Adorini, L.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1996-02-01
- Volume
- 183
- Issue
- 2
- Pages
- 485-497
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2100557339
- Cited by
- 192
- References
- 1
- FWCI
- 10.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.